Physician profile
Daniel Coulter
NPI 1942657614
$16,849.71
in general payments reported to CMS, 2019-2025
54 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $1,400 · 2021: $2,073 · 2022: $2,308 · 2023: $2,608 · 2024: $4,873 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,010 · Consulting Fee: $2,000 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,009.91 |
| Consulting Fee | $2,000.00 |
| Education | $131.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,003.60 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Abbvie INC. | $1,473.68 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,380.78 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,113.68 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $895.41 | 2019-2025 | |
| Novo Nordisk INC | $854.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $622.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $571.51 | 2019-2025 | |
| Astellas Pharma US INC | $461.31 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $454.03 | 2019-2025 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $445.90 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $445.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $409.65 | 2019-2023 | |
| Harmony Biosciences LLC | $398.38 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.63 | 2019-2025 | Jardiance, Tradjenta |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.02 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $229.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $183.06 | 2022-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $167.72 | 2022 | |
| Amarin Pharma, INC. | $157.35 | 2020-2022 | |
| Exact Sciences Corporation | $148.47 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $141.45 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $127.05 | 2020-2025 | Proclaim, Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $125.95 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $91.71 | 2021 | |
| Neurocrine Biosciences, INC. | $90.86 | 2019 | |
| Phathom Pharmaceuticals, INC. | $86.75 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $82.53 | 2022-2023 | Gattex, Trintellix |
| Gilead Sciences, INC. | $79.63 | 2019 | |
| Axsome Therapeutics, INC. | $78.20 | 2024-2025 | Auvelity, Sunosi |
| Esperion Therapeutics, INC. | $73.41 | 2020-2025 | Nexletol |
| Sanofi Pasteur INC. | $73.29 | 2021-2023 | |
| Dexcom, INC. | $68.85 | 2021-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $67.76 | 2020-2024 | Yupelri |
| Cardiovascular Systems INC. | $60.51 | 2021 | |
| Vanda Pharmaceuticals INC. | $57.10 | 2025 | Fanapt |
| Eisai INC. | $54.38 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $50.58 | 2021-2023 | Givlaari |
| Seqirus USA INC | $50.42 | 2022-2024 | Fluad, Flucelvax |
| Lundbeck LLC | $47.01 | 2022-2024 | Rexulti |
| Corcept Therapeutics | $46.85 | 2025 | Korlym |
| Allergan, INC. | $36.57 | 2020 | |
| Optinose US, INC. | $33.49 | 2024 | |
| Sumitomo Pharma America, INC. | $30.89 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $29.96 | 2019-2023 | Strensiq |
| Tactile Systems Technology INC | $22.05 | 2025 | Flexitouch Plus, Nimbl |
| Pulmonx Corporation | $16.16 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $13.94 | 2020 | |
| Bioventus LLC | $13.56 | 2025 | Gelsyn-3 |
| Indivior INC. | $13.28 | 2024 | Sublocade |
| Ironwood Pharmaceuticals, INC | $11.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.50 | 2020 | |
| Mayne Pharma Commercial LLC | $5.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coulter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.